{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:49Z","timestamp":1790812129551,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jacl.2025.07.005","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T23:21:17Z","timestamp":1752880877000},"page":"1223-1233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-0633","authenticated-orcid":false,"given":"Robert S.","family":"Rosenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4817-0378","authenticated-orcid":false,"given":"Richard T.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Qiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-790X","authenticated-orcid":false,"given":"Manish P.","family":"Ponda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpana","family":"Waldron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.jacl.2025.07.005_bib0001","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacl.2025.07.005_bib0002","doi-asserted-by":"crossref","first-page":"A147","DOI":"10.1016\/j.chest.2020.05.591","article-title":"Hypertriglyceridemia-induced acute pancreatitis","volume":"157","author":"Ibrahim","year":"2020","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.jacl.2025.07.005_bib0003","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/j.gastro.2012.08.002","article-title":"Burden of gastrointestinal disease in the United States: 2012 update","volume":"143","author":"Peery","year":"2012","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jacl.2025.07.005_bib0004","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/MPA.0000000000001275","article-title":"Trends and outcomes of hospitalizations related to acute pancreatitis: epidemiology from 2001 to 2014 in the United States","volume":"48","author":"Gapp","year":"2019","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.jacl.2025.07.005_bib0005","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12944-021-01488-8","article-title":"The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis","volume":"20","author":"Sanchez","year":"2021","journal-title":"Lipids Health N Hav Dis"},{"key":"10.1016\/j.jacl.2025.07.005_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108544","article-title":"Severe hypertriglyceridemia: existing and emerging therapies","volume":"251","author":"Malick","year":"2023","journal-title":"Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.jacl.2025.07.005_bib0007","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s11883-023-01140-z","article-title":"Updates in drug treatment of severe hypertriglyceridemia","volume":"25","author":"Gouni-Berthold","year":"2023","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"10.1016\/j.jacl.2025.07.005_bib0008","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jacl.2025.07.005_bib0009","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.eprac.2024.09.016","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline on pharmacologic management of adults with dyslipidemia","volume":"31","author":"Patel","year":"2025","journal-title":"Endocrine Pract"},{"issue":"2","key":"10.1016\/j.jacl.2025.07.005_bib0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jacl.2025.07.005_bib0011","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jacl.2025.07.005_bib0012","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J Lipid Res"},{"issue":"7","key":"10.1016\/j.jacl.2025.07.005_bib0013","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J Lipid Res"},{"issue":"18","key":"10.1016\/j.jacl.2025.07.005_bib0014","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jacc.2021.08.051","article-title":"New therapies for lowering triglyceride-rich lipoproteins: JACC Focus Seminar 3\/4","volume":"78","author":"Rosenson","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.07.005_bib0015","unstructured":"European Medicines Agency. Evkeeza 150 mg\/mL concentrate for solution for infusion [summary of product characteristics]. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/evkeeza-epar-product-information_en.pdf. Accessed December 6, 2024."},{"key":"10.1016\/j.jacl.2025.07.005_bib0016","unstructured":"Ultragenyx Pharmaceutical Inc. EVKEEZA\u24c7 (evinacumab) for injection (150 mg\/mL concentrate for solution for infusion). Available at: https:\/\/pdf.hres.ca\/dpd_pm\/00072602.PDF. Accessed December 6, 2024."},{"key":"10.1016\/j.jacl.2025.07.005_bib0017","unstructured":"Regeneron Pharmaceuticals Inc. EVKEEZA\u24c7 (evinacumab-dgnb) prescribing information. Available at: https:\/\/www.regeneron.com\/sites\/default\/files\/Evkeeza_PI.pdf. Accessed December 6, 2024."},{"key":"10.1016\/j.jacl.2025.07.005_bib0018","unstructured":"Ultragenyx Japan K.K. Ultragenyx obtains marketing authorization for Evkeeza\u24c7 Intravenous Drip Infusion 345 mg for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) in Japan. Available at: https:\/\/www.ultragenyx.com\/wp-content\/uploads\/2024\/01\/Ultragenyx_Press_Release_Evkeeza_solution_345mg_received_approval_for_manufacturing_and_marketing_in_Japan_01182024.pdf. Accessed December 6, 2024."},{"key":"10.1016\/j.jacl.2025.07.005_bib0019","unstructured":"Medicines & Healthcare Products Regulatory Agency. Summary of product characteristics: evkeeza 150 mg\/ml concentrate for solution for infusion. Available at: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/ddc7ec0afc16701e8a04453666e309baea3915d4. Accessed December 6, 2024."},{"issue":"20","key":"10.1016\/j.jacl.2025.07.005_bib0020","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacl.2025.07.005_bib0021","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society Clinical Practice Guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.jacl.2025.07.005_bib0022","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1194\/jlr.D071696","article-title":"Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics","volume":"58","author":"Dunbar","year":"2017","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.jacl.2025.07.005_bib0023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11883-024-01258-8","article-title":"The emerging potential of apolipoprotein C-III inhibition for ASCVD prevention: a state-of-the-art review","volume":"27","author":"Maidman","year":"2024","journal-title":"Curr Atheroscler Rep"},{"issue":"19","key":"10.1016\/j.jacl.2025.07.005_bib0024","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacl.2025.07.005_bib0025","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.jacl.2025.07.005_bib0026","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425003459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:49:29Z","timestamp":1772894969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425003459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1933287425003459"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.07.005","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}